Pharmaxis’ Bronchitol Will Face Efficacy Questions At FDA Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Several statistical issues, including differential rates of missing data between treatment arms in the pivotal studies, make it difficult to assess mannitol’s benefit in cystic fibrosis patients, FDA says in briefing documents for the Pulmonary-Allergy Drugs Advisory Committee’s Jan. 30 meeting.
You may also be interested in...
Chiesi Takes CF Product To Advisory Cmte. With Modest Efficacy, Many Questions
Bronchitol is set to make its second appearance before a US FDA advisory committee, and Chiesi hopes to rely on the drug’s novel mechanism of action and the unmet need in cystic fibrosis to overcome the agency’s concerns about the underlying clinical data.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.